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Periodontitis and other bone loss diseases, decreasing bone volume and strength, have a significant impact on millions of people
with the risk of tooth loss and bone fracture. The integrity and strength of bone are maintained through the balance between
bone resorption and bone formation by osteoclasts and osteoblasts, respectively, so the loss of bone results from the disruption
of such balance due to increased resorption or/and decreased formation of bone. The goal of therapies for diseases of bone loss is
to reduce bone loss, improve bone formation, and then keep healthy bone density. Current therapies have mostly relied on long-
termmedication, exercise, anti-inflammatory therapies, and changing of the life style. However there are some limitations for some
patients in the effective treatments for bone loss diseases because of the complexity of bone loss. Interleukin-10 (IL-10) is a potent
anti-inflammatory cytokine, and recent studies have indicated that IL-10 can contribute to the maintenance of bone mass through
inhibition of osteoclastic bone resorption and regulation of osteoblastic bone formation. This paper will provide a brief overview
of the role of IL-10 in bone loss diseases and discuss the possibility of IL-10 adoption in therapy of bone loss diseases therapy.
1. Introduction
Bone remodeling is a dynamic lifetime process through the
resorption of old bone by osteoclasts and the subsequent
synthesis of new bone by osteoblasts. These two closely
coupled events are responsible for renewing the skeleton
while maintaining its anatomical and structural integrity.
Under normal conditions, the amount of absorbed bone
equals the regenerated bone; bone remodeling proceeds in
recycles inwhich osteoclasts adhere to bone and subsequently
remove it by acidification and proteolytic digestion. Once
the osteoclasts leave the resorption sites, osteoblasts will
migrate to the resorption sites and start forming new bone
by secreting osteoid, which is eventually mineralized [1, 2].
Osteoclasts are specialized cells derived from haemato-
poietic lineage such asmonocytes/macrophage.They develop
and adhere to bone matrix and then secrete acid and lytic
enzymes to degrade bone [3, 4]. The increase in number
and/or activity of bone-resorbing osteoclasts could con-
tribute to excessive bone resorption, disrupts the balance
between bone resorption and bone formation, and results
in the loss of bone. This may consequently lead to the fol-
lowing bone loss diseases: osteoporosis, rheumatoid arthritis,
periodontal bone absorption, malignancy-related skeletal
diseases, and so on [5–8].
Periodontitis, a bone loss disease, is a chronic inflamma-
tory disease. As for periodontitis, destruction of connective
tissue and alveolar bone can occur and finally results in the
loss of teeth. Therefore, it is very critical for periodontists
if we can develop a method to inhibit bone resorption and
promote alveolar bone regeneration. Given the role of IL-10
in bone remodeling, the use of IL-10 for inhibiting bone
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resorption and reducing inflammation may be beneficial for
the treatments of periodontitis.
2. Cytokines in Bone Metabolism
It is well known that bone loss diseases are affected by
inflammation, hereditary factors, hormones, aging, life style,
and so on. Hence, it is imperative for us to develop other ther-
apeutic methods to improve clinical outcome. For decades,
a number of attempts have been made to achieve good
prognosis for these diseases [9–11]. In particular, much
attention has been paid to the importance of cytokines in
the pathogenesis of bone resorption. The existing evidences
suggested that various cytokines play an important role in
both physiologic and pathologic bone resorption [12–14].
Numerous of cytokines exists in the bone tissue, and their
functions in bone formation and resorption are still not
well understood. It has been demonstrated that receptors in
the proinflammatory cytokines IL-1, IL-6, and TNF-𝛼 are
present on osteoclast precursor cells and mature osteoclasts
[13, 15]. A breakthrough in understanding the mechanism
is that cytokines regulate proliferation and differentiation of
mononuclear preosteoclasts into osteoclast progenitors and
fusion of the preosteoclasts into multinucleated osteoclasts
[16, 17]. Zhao and coworkers showed that the receptor
activator of nuclear factor 𝜅B ligand (RANKL), which was
secreted by live osteocytes, promotes osteoclastogenesis [18].
Moreover, osteoprotegerin (OPG), as a soluble decoy receptor
for RANKL, is also a crucial regulator of osteoclastogenesis
[14, 19–22]. OPG can block osteoclastogenesis and maintain
normal bone mass by binding RANKL and blocking inter-
action with RANK. Furthermore, in vitro and in vivo studies
have shown thatmany cytokines elaborated by inflammation,
tumor necrosis factor 𝛼 (TNF-𝛼), and IL-1 may be attributed
to osteoclast differentiation and activation by regulating the
production of RANKL and/or OPG [4, 7, 23].
In addition, TNF-𝛼 and IL-1 promote resorption activity
of osteoclasts by increasing macrophage colony stimulating
factors (M-CSF). M-CSF can bind to its receptor, c-fms, on
precursor cell for differentiation via the actions of RANKL
[24].
3. IL-10 and Bone Metabolism
IL-10 is a potent anti-inflammatory cytokine that suppresses
both immunoproliferative and inflammatory responses. So
understanding of the role of IL-10 in the bone loss diseases
is essential. IL-10 was first identified at molecular level by
the DNAX Research Institute [25]. As a factor produced
by T helper 2 (Th2) cells, IL-10 inhibits the production of
cytokines by Th1 cells [26]. IL-10 has been subsequently
shown additional stimulative effects on thymocytes, B cells,
andmast cells. It is well known that IL-10 is actually produced
by many other cell types, including B cells, mast cells,
eosinophils, macrophages, and dendritic cells (DCs), and a
large number of subsets of T cells such as CD8+ T cells and
antigen-driven regulatory CD4+ T cells [27] in mouse and
human systems.
IL-10 can downregulate the synthesis of proinflammatory
cytokines and chemokines, such as IL-1, IL-6, and TNF-
𝛼 [28, 29]. It can also downregulate the synthesis of nitric
oxide, gelatinase, and collagenase. Specific neutralization of
IL-10 results in upregulating the synthesis of IL-1 and TNF-
𝛼 [30, 31]. Therefore, IL-10 has been also regarded as an
important regulator of bone homeostasis, in homeostatic and
inflammatory conditions [32–34].
Recent studies have indicated that the polymorphisms
of IL-10 gene, which may affect IL-10 production, are
associated with reduced bone mineral density (BMD) in
postmenopausal women who were prone to suffered from
osteoporosis [35, 36]. However, serum levels of IL-10 are sig-
nificantly lower in the postmenopausal osteoporotic patient
than in postmenopausal healthy women [37]. The low level
of IL-10 results in the insufficient inhibition of the proin-
flammatory cytokines and collagenase, which may have an
impact on osteoporosis development [38]. Animal studies
have confirmed that lack of IL-10 leads to femur bone loss
[39, 40] and alveolar bone loss [33, 40, 41], providing further
evidence of bone metabolism by IL-10 [39]. In the oral bone
lytic diseases, such as periodontitis and periapical lesions, IL-
10 has been shown as an important regulator of alveolar bone
homeostasis [40, 42–44]. Herein, we speculate that IL-10 acts
on the bone loss diseases based on the following criteria.
(1) IL-10 Inhibits Osteoclasts Formation. Xu and coworkers
showed that IL-10 had potent inhibitory effects on osteo-
clastogenesis in the 1990s [45]. Others suggested IL-10 could
directly inhibit osteoclast formation [46, 47]. The inhibitory
effect of IL-10 on osteoclast formation through a direct action
on osteoclast precursors was reported [47, 48]. Moreover,
enhanced osteoclastogenesis has been observed in cultures
of bone marrow macrophages deficient in IL-10 production
[49]. The molecular mechanism of this inhibition indicated
that IL-10 upregulated osteoprotegerin (OPG) expression but
downregulated expression of the receptor activator of NF-
𝜅B ligand (RANKL) and colony-stimulating factor-1 (CSF-1)
[50]. In vitro test showed that IL-10 may inhibit osteoclasto-
genesis by reducing nuclear factor of activated T cells (NFAT)
c1 expression [46, 51].
Bone resorptionwasmediated largely by local production
of proinflammatory cytokines, such as TNF-𝛼 and IL-1 [4, 17,
23, 25, 26]. These cytokines may act by directly enhancing
proliferation and activity of cells in the osteoclast lineage or
by indirectly affecting the production of osteoclast differenti-
ation factors such as RANKL andOPG via osteoblast/stromal
cells [4]. IL-10 has been recognized to have potent anti-
inflammatory activity for a long time, and it is demonstrated
to be an important endogenous suppressor of infection-
stimulated bone resorption in vivo [52]. In conclusion, IL-10
suppresses osteoclastic differentiation via the above several
aspects.
(2) IL-10 Promotes Osteoblastic Differentiation Overall. van
Vlasselaer and coworkers suggested that IL-10 downreg-
ulated early steps of osteogenic differentiation in murine
bone marrow cells through the inhibition of transforming
growth factor-beta 1 (TGF-𝛽1) production [53, 54]. How-
ever, Dresner-Pollak and coworkers indicated that reduced
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generation of osteoblasts has been found in bone marrow
cell cultures obtained from IL-10(−/−) mice, and IL-10(−/−)
mice develop the hallmarks of osteoporosis, that is, decreased
bone mass, increased mechanical fragility, and suppressed
bone formation [39]. They also suggested that cytokines and
inflammatory mediators, including TNF-𝛼, IFN-𝛾, and NO,
which are known to be upregulated in the IL-10(−/−) mice,
had deleterious effects on the differentiation, proliferation,
and function of osteoblasts [39]. The inhibitory effects in
early stages of osteogenic differentiationmight be neutralized
eventually by the downregulation of inflammatory cytokines
of infection, such as TNF-𝛼. In other words, IL-10 enhances
the osteoblastic differentiation eventually.
4. IL-10 in Periodontal Diseases and
Periodontal Treatment
As an important anti-inflammatory cytokine, IL-10 plays a
vital role in periodontal diseases. The lockout of IL-10 may
result in accelerating alveolar bone absorption and decreasing
bone formation [38–42]. Meanwhile, animal models by the
IL-10 knockout mice demonstrated that the IL-10 had the
anti-inflammation effect in periodontitis [43]. Currently
some studies revealed that polymorphisms of IL-10 gene
promoter were involved in the development of periodontal
diseases. The specific genotypes (−819TT/−592AA) with low
IL-10 expression may aggravate the inflammation response
and cause the overgrowth of gingival [55]. The haplotype
ATA of IL-10, as a “low interleukin-10 producer,” was proved
as a risk indicator for generalized aggressive periodontitis
[56]. Moreover, others observed that these single-nucleotide
polymorphisms (SNPs) of IL-10, including−1082(−1087)A/G,
−819(−824)C/T and −592(−597)C/A, were associated with
the generalized chronic periodontitis and/or aggressive peri-
odontitis [57–60], which elucidates the role of IL-10 in
periodontal diseases.
Smoking is well recognized as a risk factor of periodonti-
tis, and it has been reported that smokers are several times
more likely to suffer from periodontitis than nonsmokers
[61]. Ebersole and coworkers indicated that smoking may
cause the remarkableTh2 response and the elevating of IL-10
[62, 63], suggesting that the periodontitis could be worse by
smoking.
Applications of IL-10 have been explored by several
animal models [38–41, 64–66]; further evidences are still
needed in the future study.
5. Future Perspective
Diseases of the bone loss are severely influencing quality
of people’s health and life. As IL-10 can contribute to the
maintenance of bone mass by inhibition of osteoclastic bone
resorption and stimulation of osteoblastic bone formation,we
hypothesize that utility of IL-10 will be a novel therapeutic
strategy in bone loss diseases. It might especially be an
attractive treatment option for inflammation-related bone
loss, such as periodontal diseases, periapical lesions, and
inflammatory bowel disease. The use of IL-10 will be helpful
to accelerate the healing process of fracture and enhance
osseointegration with dental implantation in osteoporotic
subjects.
6. Conclusions
The strategy of inhibiting osteoclastogenesis and enhancing
osteoblastic differentiation can be beneficial for the treatment
of bone loss diseases. Given the fact that IL-10 can inhibit
bone loss, the use of IL-10 will be an effective therapeutic
method for periodontitis and other bone loss diseases. We
expect that IL-10 protein therapy could be tested by exam-
ining bone loss in ligature-induced periodontitis and bone
turnover in ovariectomized rats. The strategies presented in
this review can facilitate the future research on IL-10 in bone
loss diseases.
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